Every decision that touches the protocol surface - verifier releases, BioGate parameter changes, council policy shifts, disclosed incidents - appends here. Entries cannot be quietly amended; corrections post as new entries that reference the original.
adr-00082026-04-28First public push of Peptide MD. Includes the cohort registry, the OEA-V1 frozen test vectors, dossier PDF generation under the seven-rule export gate, and Mol* viewer integration for peptides with RCSB structures. Verifier published as @peptide-md/verifier@0.1.0-experimental.1.
adr-00072026-04-28All six council seats declared open. Until each seat is filled, every protocol-tier promotion and verifier release requires dual sign-off from the founding team plus one remaining seat. The signature record is public on this page.
adr-00062026-04-28Three frozen vectors (alpha, beta, gamma) published under CC0. Hashes will not change without a major version bump that ships new vectors alongside. The -9.0 dialect literal edge is exercised by vector beta; the odd-count Merkle duplication rule by vector gamma.
adr-00052026-04-27Public-tier screen now matches against UniProt toxin profiles, the Australia Group select-agent registry, and a curated cathelicidin-family profile-HMM set. Sequence-window threshold: 8-residue overlap = AMBER, ≥12 = RED. Private-tier review pending biosecurity seat.
adr-00042026-04-26PDA-V1 design attestations and OEA-V1 reveal attestations form a single cryptographic chain owned end-to-end by Peptide MD. PDA binds peptide design to its inputs; OEA binds the human-use cohort to its endpoint. External design pipelines can submit PDA-V1 bundles via /import-pda; the verifier accepts them under source: "external".
adr-00032026-04-26The core orchestration codebase remains private (biosecurity-relevant artifacts, partner-confidential interfaces). The verifier, the test vectors, the white paper, the architecture, the changelog, and the contribution graph are public. Open-trust posture: the code that issues a commitment can stay private, but the code and inputs that verify it cannot.
adr-00022026-04-25Cohort treasuries underwrite recruitment and CRO contracts. Royalty cascade splits revealed-OEA outcome revenues 25% / 15% / 35% / 20% / 5% across cohort treasury, participants, originating researchers, stakers, and Peptide MD protocol fee. No native token issuance until jurisdictional review completes; $PMD is a placeholder governance primitive on /token.
adr-00012026-04-25Peptide MD ships a six-stage thesis pipeline: signal intake, novelty scoring, thesis generation, scenario planning, dossier export, and endpoint evaluation. Stage six is the outcome layer - pre-registered cohort runs and OEA reveals attach an outcome-conditioned probability to every candidate that passed the dossier gate.
incident-00012026-04-24First public surface goes up tomorrow. This entry is the empty marker; the changelog will append every disclosure, every verifier regression, and every BioGate parameter change as they happen.